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Recently, EDI3 was identified as a key factor for choline metabolism 
that controls tumor cell migration 
and is associated with metastasis in 
endometrial carcinomas. EDI3 cleaves 
glycerophosphocholine (GPC) to form 
choline and glycerol-3-phosphate (G3P). 
Choline is then further metabolized to 
phosphatidylcholine (PtdC), the major 
lipid in membranes and a key player 
in membrane-mediated cell signaling. 
The second product, G3P, is a precursor 
molecule for several lipids with central 
roles in signaling, for example lyso-
phosphatidic acid (LPA), phosphatidic 
acid (PA) and diacylglycerol (DAG). 
LPA activates intracellular signaling 
pathways by binding to specific LPA 
receptors, including membrane-bound 
G protein-coupled receptors and the 
intracellular nuclear receptor, PPARγ. 
Conversely, PA and DAG mediate sig-
naling by acting as lipid anchors that 
bind and activate several signaling pro-
teins. For example, binding of GTPases 
and PKC to PA and DAG, respectively, 
increases the activation of signaling 
networks, mediating processes such as 
migration, adhesion, proliferation or 
anti-apoptosis—all relevant for tumor 
development. We present a concept 
by which EDI3 either directly gener-
ates signaling molecules or provides 
“membrane anchors” for downstream 
signaling factors. As a result, EDI3 
links choline metabolism to signaling 
activities resulting in a more malignant 
phenotype.
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Key Role of EDI3 in Choline  
Metabolism: The Missing Link  
in the Kennedy Pathway
In a screening set of endometrial carci-
nomas consisting of pairs of tumor tissue 
with identical histopathological features, 
which later did or did not form metas-
tasis, we identified three differentially 
expressed genes. However, only one—
EDI3—was confirmed to be positively 
associated with metastasis in independent 
sets of carcinomas.1 EDI3 showed a 99% 
homology to glycerophosphodiesterase 
5 (GDE5), a so-far poorly characterized 
member of the GDE protein family. No 
other member of the family was, at the 
time, implicated in tumor development. 
As an initial step to understand the func-
tion of EDI3, we tried to identify EDI3’s 
preferred substrate. Therefore, possible 
candidate compounds were incubated 
with both lysates from cells overexpress-
ing EDI3 and recombinant EDI3 pro-
tein, resulting in efficient cleavage of 
glycerophosphocholine (GPC) to form 
choline and glycerol-3-phosphate (G3P) 
(Fig. 1A). To analyze whether EDI3 also 
influences intracellular concentrations 
of choline metabolites, we performed 
siRNA knockdowns in several tumor 
cell lines (MCF7, MDA-MB-231 and 
AN3-CA). Knockdown of EDI3 always 
led to increased intracellular levels of the 
substrate, GPC and decreased levels of 
phosphocholine (PC) (Fig. 1B), formed 
from the phosphorylation of choline by 
choline kinase and representing the first 
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2 Cell Cycle volume 11 issue 24
such as the Kennedy pathway (Fig. 2). 
However, the enzyme responsible for 
the cleavage remained unknown. Our 
of choline needed for several down-
stream signaling pathways, including 
the synthesis of various phospholipids, 
step of the Kennedy pathway (Fig. 2). 
Production of choline from the cleavage 
of GPC provides an important source 
Figure 1. EDi3 cleaves glycerophosphocholine (GPC) to choline and glycerol-3-phosphate (G3P). (A) activity of the purified EDi3 protein which metab-
olizes GPC to form G3P. additional generation of choline has been demonstrated by an enzyme-coupled spectrophotometric assay. (B) Knockdown of 
EDi3 in MCF-7 cells increases intracellular concentrations of the substrate GPC and decreases phosphocholine (PC), which is formed from the product, 
choline (from Stewart et al., 2012).1
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Contribution of EDI3’s  
Downstream Metabolites to  
Cellular Signaling
Signaling via lysophosphatidic acid. Many 
open questions remain from our original 
work with EDI3, including how to resolve 
EDI3’s activity with its downstream sig-
naling and metastatic phenotype. EDI3 
was shown to influence lipids important 
for signaling, such as LPA, PA and DAG. 
LPA is a ubiquitous single-chain phospho-
lipid that acts both as an intermediate for 
the de novo synthesis of glycerolipids and, 
extracellularly, as a lipid mediator that 
binds and activates specific G protein-
coupled receptors. This powerful signaling 
molecule mediates downstream signal-
ing pathways via Rho, Cdc42 and Rac 
GTPases, PI3K-Akt, Ras-MAPK, phos-
pholipase C and PKC to control cellular 
activity led to reduced cell migration.1 A 
general phosphodiesterase inhibitor that 
was identified after screening with puri-
fied protein as capable of inhibiting EDI3 
caused a similar effect. Accordingly, 
overexpression of EDI3 in MCF-7 cells 
increased migration activity. To identify 
the mechanism by which EDI3 influences 
cell migration, we tested numerous pos-
sible signaling pathways. Interestingly, 
only PKC was functionally relevant in 
both MCF-7 and AN3-CA cells. EDI3 
siRNA decreased PKCα protein lev-
els with the opposite effect observed in 
cells overexpressing EDI3. Activation 
or inhibition of PKCα caused increased 
or decreased migration, respectively. 
Moreover, siRNA knockdown of PKCα 
in EDI3-overexpressing cells countered 
the increased migration rate due to EDI3 
overexpression.
experiments using specific siRNA oligos 
to knockdown EDI3, together with EDI3 
enzymatic assays with purified protein, 
demonstrated that EDI3 is the responsi-
ble enzyme providing choline for the first 
step of the Kennedy pathway.
EDI3 Controls Tumor Cell  
Migration via PKC Signaling
To identify possible consequences of 
altered choline metabolism, we tested 
various cell lines (MCF7, MDA-MB-231 
and AN3-CA) after EDI3 siRNA knock-
down, using only conditions where EDI3 
activity was reduced by approximately 
70%. Decreased EDI3 expression and 
activity did not influence most of the 
analyzed endpoints, including prolif-
eration and apoptosis. However, in all 
analyzed cell lines, a decrease in EDI3 
Figure 2. Concept of the link between choline metabolism and intracellular signaling. a proposed concept of how EDi3 links choline metabolism to 
altered signaling network activities. Choline is further metabolized to the major membrane lipid PtdC. tumor cells have a higher demand for this lipid 
to facilitate restructuring of the cell membrane for division and migration. G3P fuels the G3P-LPa-Pa-DaG pathway which creates anchoring points for 
GtPases and PKC and activates intracellular signaling (from Marchan et al., 2012). abbreviations: CDP-Cho, cytidine 5’-diphosphocholine; CHK, choline 
kinase; Ct, CDP, phosphocholine cytidyltransferase; DaG, diacylglycerol; DaGK, DaG kinase; G3P, glycerol-3-phosphate; LPL, lysophospholipase; GPat, 
G3P acyltransferase; LPaat, LPa acyltransferase; PaP, Pa phosphatase; PCt, diacylglycerol choline phosphotransferase; PLa, phospholipase a; PLB, 
phospholipase B; PLC, phospholipase C; PLD, phospholipase D; PtdC, phosphatidylcholine (from Marchan et al., 2012).22
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PKC’s substrate binding site of a pseu-
dosubstrate, facilitating the binding and 
activation of PKC’s true targets. PKC 
binds DAG and PS via its N-terminal C1 
domain. A ring of positive residues at the 
middle of the domain facilitates binding to 
PS and other anionic phospholipids. The 
interaction between the positive residues 
of the C1 domain and anionic phospho-
lipids repositions the C1 domain, allow-
ing it to insert itself into the membrane 
bilayer and bind DAG.6 This binding is 
facilitated by a groove of hydrophobic resi-
dues at the upper third of the C1 domain, 
and the strength of binding is determined 
by a conserved residue at position 22.7 
Although DAG was not directly measured 
in our study, it is directly formed from the 
de-phosphorylation of PA by PA phospha-
tase. Alternatively, DAG can be produced 
from the hydrolysis of PtdC, many species 
of which were altered by EDI3 knock-
down (Fig. 3).
The concept of membrane anchors 
resulting from choline metabolism. 
Numerous signaling proteins require 
anchoring to membrane lipids in order to 
achieve full activity. Membrane binding 
leads to downstream signaling that regu-
lates critical processes for tumor develop-
ment, such as proliferation, migration, 
adhesion and apoptosis. Possible mem-
brane anchors relevant for EDI3 include 
DAG and PA. Like LPA, DAG and PA 
can be directly formed from the hydro-
lysis of PtdC molecules (Fig. 2), which, 
in addition to providing lipid signaling, 
are also necessary to facilitate restructur-
ing of the cell membrane for division and 
migration, both critical during tumor 
development.
Knocking down EDI3 in several cell 
lines decreased PKCα, which is activated 
upon binding to DAG and the anionic 
phospholipid, phosphatidylserine (PS). 
The binding of PKC to these lipids frees 
migration, invasion, proliferation, differen-
tiation, cytoskeletal reorganization, angio-
genesis, inflammation and resistance to 
apoptosis.2,3 LPA arises from several meta-
bolic pathways in the cell. Phospholipids 
are hydrolyzed by the sequential activity 
of phospholipase D (PLD) followed by 
phospholipase A2 (PLA
2
), to form LPA. 
Alternatively, lysophosphatidylcholine 
is cleaved by the ectoenzyme, autotaxin, 
which has phospholipase D activity to form 
extracellular LPA. Perhaps most specific 
for EDI3 is the direct acylation of G3P, 
EDI3’s enzymatic product, by G3P acyl-
transferase to form LPA. LPA formed via 
the latter pathway has recently been shown 
to activate the peroxisome proliferator acti-
vated receptor-γ (PPARγ).4 PPARγ binds 
to its PPAR response elements (PPRE) 
found on several genes with diverse cellular 
functions, such as fatty acid metabolism, 
adipocyte differentiation, lipid transport 
and proliferation.5
Figure 3. Knockdown of EDi3 in MCF7 cells decreases the concentrations of lysophosphatidic acid (LPa) and phosphatidic acid (Pa) species. Moreover, 
the levels of most phosphatidylcholine (PtdC) species are reduced (from Stewart et al., 2012).1
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Table 1. Overview of studies that analyze GPC, PC and Cho in relation to malignant transformation
Key message Reference
Epithelial ovarian cancer cell lines and normal ovary epithelial cells were compared. the cancer cells had higher PC 
concentrations and a lower GPC/PC ratio compared with the normal cells.
iorio et al., 200527
Human liver tumor biopsies showed significant elevation of PC and reduction of GPC compared with histologically 
normal liver tissue.
Bell et al., 199328
Choline phospholipid metabolism was compared in cultivated normal human mammary epithelial cells, immortal-
ized, as well as oncogene transformed cells. a “glycerophosphocholine to phosphocholine switch” was observed 
with immortalization and oncogene transformation. PC and total Cho levels increased with progression from nor-
mal to immortalized to oncogene-transformed cells.
aboagye and Bhujwalla, 199929
Compared with normal human mammary epithelial cells, breast cancer cell lines show increased PC, increased 
choline kinase activity and increased choline transport rates.
Eliyahu et al., 200730
the absolute concentration of all Cho containing compounds (GPC+PC+Cho) was higher in high-grade than low 
grade gliomas. in low grade gliomas, the signal was largely due to GPC. in high grade gliomas GPC, PC, and Cho 
contributed similarly.
Sabatier et al., 199931
Liver tumors and healthy liver tissues were compared. Liver tumors showed increased PC signals and decreased 
GPC signals.
Cox et al., 199232
Breast cancer patients (n = 89) received neoadjuvant chemotherapy with epirubicin or paclitaxel. tumor biopsies 
were analyzed before and after treatment. Survivors experienced a decrease in choline containing compounds, 
including GPC and PC.
Cao et al., 2012b33
Biopsies from 160 breast cancer patients were examined. Mr based metabolomics showed differences between 
hormone receptor positive and negative carcinomas, whereby hormone receptor negative carcinomas had higher 
levels of GPC, Cho and PC than hormone receptor positive carcinomas.
Giskeodegard et al., 201034
altered phospholipid metabolism is observed in tumors, whereby the malignant choline metabolite profile is 
characterized by low GPC and high PC. the GPC metabolizing enzyme GDPD5 shows higher expression levels in 
estrogen receptor negative compared with estrogen receptor positive breast carcinomas.
Cao et al., 2012a35
Mouse tumor model (SCiD mice) was established with biopsy tissue from one primary luminal- and one basal-like 
mammary carcinoma. the tumor tissue of the luminal-like tumor had higher PC but lower GPC compared with the 
basal-like tumor.
Moestue et al., 201036
Comparing paired samples of human lung cancer tissue and noninvolved adjacent tissue showed increased PC and 
GPC in tumor tissue.
rocha et al., 201037
Breast cancer tissue and non-involved breast tissue of 16 patients were compared. increased levels of Cho, PC and 
GPC were observed in tumor tissue.
Gribbestad et al., 199938
Prostate cancer has higher levels of PC and GPC compared with normal prostate. ackerstaff et al., 200139
Chronic lymphocytic leukemia lymphocytes (CLL) and normal lymphocytes were compared. CLL had higher PC 
and higher GPC concentrations.
Franks et al., 200240
High-grade prostate carcinomas have higher concentrations of PC and GPC than low-grade prostate carcinomas. Keshari et al., 201141
Grade 3 astrocytomas had higher concentrations of PC than grade 2 astrocytomas. GPC increased with the prolif-
eration marker Ki-67.
McKnight et al., 201142
Low and high grade gliomas were compared for GPC and PC concentrations. GPC was the dominant metabolite in 
high grade gliomas.
righi et al., 200943
PC and GPC were higher in prostate cancer compared with benign prostate tissues. Swanson et al., 200844
total choline concentrations were elevated in untreated pediatric brain tumors compared with controls. Moreover, 
the GPC to PC ratio decreased in the tumors.
albers et al., 200545
the studies support an overall increase in choline metabolism including metabolites of the Kennedy pathway, such as PC. However, depending on the 
tumor type, there were variable results with respect to the GPC/PC ratio. to understand this discrepancy, it may be important to differentiate between 
the metabolic flux through the Kennedy pathway and the concentration of GPC. increased metabolic flux mediated by for example, EDi3 and CHK may 
decrease GPC concentrations. However, a tumor may evolve further mechanisms to enhance GPC concentrations. this will, in turn, further increase 
the metabolic flux through the Kennedy pathway, supporting the need to consider the change to choline metabolism as a whole rather than a single 
metabolite (from Marchan et al., 2012).22
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PA is a backbone lipid for many mem-
brane phospholipids. In addition to its 
importance as a precursor molecule in 
phospholipid synthesis and membrane 
curvature, PA is increasingly recognized 
for its role as a potent regulator of intra-
cellular signaling, influencing cell growth 
and proliferation, cytoskeletal reorga-
nization, migration and invasion and 
membrane trafficking.8,9 Knocking down 
EDI3 in our study decreased all species 
of PA measured. PA is generated via vari-
ous reactions in the cell, and perhaps most 
relevant for EDI3 is the acylation of LPA, 
a direct product of EDI3’s G3P product. 
Alternative pathways include the hydroly-
sis of PtdC by phospholipase D to form 
PA and choline and the phosphorylation 
of DAG by DAG kinase. PLD activ-
ity is upregulated in many cancers;10-12 
therefore, PLD is intensely studied for its 
potential as a therapeutic target.12
PA’s activity and importance in sig-
naling is centered on its ability to bind 
and activate several signaling proteins, 
including members of the Ras superfam-
ily of GTPases, such as the small GTPase, 
Rac1,13 the guanine nucleotide exchange 
factor, Epac114 and the Ras exchange fac-
tor, Sos.15 PA has been also shown to bind 
mTOR8,16 and Raf,17,18 both activators of 
cellular survival pathways. Many of PA’s 
targets are mutated or disregulated in 
cancer, making it necessary to understand 
the mechanisms underlying the interac-
tion between this lipid anchor and the 
protein targets. To facilitate anchoring, 
fatty acids, such as palmitate or myristate, 
become covalently attached to the pro-
tein. Such binding helps the protein insert 
into the membrane alongside the fatty 
acid tails of the lipid bilayer, thereby also 
drastically increasing its effective concen-
tration. Interestingly, the degree, kinet-
ics and strength of membrane anchoring 
depends both on the “fatty acid anchor,” 
i.e., its hydrophobic length and degree 
of unsaturation, and the property of the 
membrane lipid bilayer, i.e., its charge 
density, composition and lateral orga-
nization.19 For example, PA was previ-
ously shown to activate the small GTPase 
Rac113 via interaction with Rac1’s isopre-
nylated C-terminal polybasic motif. The 
concentration of PA in the membrane 
was also shown to be important for Rac1-
binding, where increasing the fraction 
of PA between 0.3 and 3% in artificially 
made membranes (liposomes) improved 
liposome binding to a purified isoprenyl-
ated Flag-V12-Rac1.
Interestingly, the existence of a poly-
basic stretch, such as that present in the 
hypervariable region of the small GTPase 
KRas4B, together with a single lipid 
anchor, such as a farnesyl residue, induces 
effective lipid sorting. Such interactions 
can form membrane-associated nanodo-
mains that could potentially operate as 
effective, high-fidelity signaling plat-
forms. Conversely, palmitoylated and 
farnesylated N-Ras proteins partition into 
the disordered regions of the lipid mem-
brane, concentrating more to the domain 
boundaries of heterogeneous membranes. 
Moreover, the G-domain mediates the 
Ras-membrane interaction by inducing 
different sets of preferred orientations in 
the active and inactive state with largely 
parallel orientation of the majority of the 
helices with respect to the membrane. 
Therefore, the distinct localization for 
the different isoforms, exposing them 
eventually to different pools of effectors 
and regulators, coupled with a differen-
tial G-domain-membrane orientation, 
suggests a synergy between this type of 
recognition motif and the specificity con-
ferred by the anchor region, thereby vali-
dating the concept of isoform specificity 
in Ras.19-21
The role of PA as a “membrane anchor” 
is of high relevance for the recently discov-
ered role of EDI3 in choline metabolism. 
EDI3 not only fuels the Kennedy pathway 
with choline to produce PtdC, but also 
provides G3P, a precursor of the signaling 
lipid, LPA, and the membrane anchor, PA 
(Fig. 2; ref. 22). PA, in turn, is metabo-
lized to DAG—an anchor for PKC.23 
Therefore, EDI3 occupies an important 
position at a metabolic crossroad, where 
downstream pathways lead to produc-
tion of the major membrane lipid, PtdC, 
signaling lipids such as LPA24 and, last 
but not least, the membrane anchor lipids 
PA and DAG, required for activation of 
GTPases and PKC, respectively (Fig. 2). 
Further work is needed to determine how 
EDI3’s function as a glycerophosphodi-
esterase alters downstream signaling and 
cellular processes.
Choline Metabolism in Relation 
to Carcinogenesis and Tumor 
Progression
Although EDI3 was originally discovered 
in metastasizing endometrial carcinomas,1 
our current knowledge on EDI3’s role 
in tumors in vivo still remains limited. 
Nevertheless, an overview of the available 
publications on choline metabolism and 
tumor development all support an overall 
increase in choline metabolism, including 
changes in GPC and PC levels (Table 1 
and ref. 22). Controversy still surrounds 
the role of GPC as a clinical marker.25 
Moreover, the role of the absolute levels of 
GPC, PC and other choline metabolites 
and their relation to one another remain 
unclear.22 Nevertheless, strong evidence 
exists that tumors have increased flux via 
the Kennedy pathway (Table 1), as shown 
by preclinical and clinical trials for inhibi-
tors against choline kinase.26 Furthermore, 
elevated levels of EDI3 in tumors that 
went on to metastasize further supports an 
elevated metabolic capacity in cancer cells. 
However, compared with choline kinase, 
antagonists of EDI3 would not only block 
the Kennedy pathway, but also antagonize 
the pathways leading to the “membrane 
anchors” PA and DAG, as well as to the 
signaling lipid LPA. Unfortunately, EDI3 
inhibitors with sufficient specificity are not 
yet available. Development of antagonists 
with adequate pharmacokinetic properties 
would certainly support the importance 
of EDI3 as a target in some cancers. Such 
antagonists would also allow us to study 
the consequences of exclusively inhibiting 
the Kennedy pathway (by choline kinase 
inhibitors) in comparison to the effect of 
additional blocking of the G3P-LPA-PA 
pathway.
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